ClinicalTrials.gg

Oligospermia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 64 studies for Oligospermia across more than 10 countries. 17 are recruiting or about to start. 43 of them are mainly about Oligospermia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06.

Status

Completed
31
Recruiting
13
Status unknown
11
Not yet recruiting
3
Terminated
3
Active, not recruiting
1

Phase

Phase 2
9
Phase 4
6
Phase 3
5
Phase 1
4
Early Phase 1
2

Where

China
9
United States
7
Egypt
6
Spain
5
Israel
4
Indonesia
3

Who develops what

Add Oligospermia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 4 programs from 2 companies, 4 with this as their studies’ main aim; 0 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Hamad Medical and Staidson (Beijing) Biopharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 4 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Sep 2027 est.STSP-0902 · Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 2 named, not the main aimNCT07833943 A Study to Evaluate the Safety and Efficacy of Multiple Dose of STSP-0902 in Patients With Oligozoospermia and/or Asthenozoospermia. — primary endpoint: Number of treatment-related adverse events as assessed by CTCAE 6.0. To evaluate the safety and tolerability of STSP-0902 injection in Patients with Oligozoospermia and/or Asthenozoospermia. · 72 enrolled
  • 15 Oct 2027 est.Antioxidants, Clomiphene, Follicle Stimulating Hormone · Hamad Medical Corporation · Phase 4 main aimNCT07862725 Comparative Efficacy of Antioxidants Alone Versus Combined Therapy With SERMs or FSH in Normogonadotropic Idiopathic OAT Patients: A Randomized Controlled Trial — primary endpoint: Change in Sperm Concentration · 360 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Oligospermia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Aromatase inhibitors 3

Coming up

0phase 3 studies under way
6studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6

Who these studies take

Of the 13 Oligospermia studies recruiting now, 4 (31%) set no upper age limit and 8 (62%) stop at 75 or younger. 2 (15%) take children under 18. 0 (0%) are for women only and 10 (77%) for men only; 4 (31%) take healthy volunteers.

Recruiting studies that take each age, of 13
AgeWomenMen
101 (8%)2 (15%)
183 (23%)9 (69%)
303 (23%)13 (100%)
403 (23%)13 (100%)
503 (23%)9 (69%)
653 (23%)5 (38%)
753 (23%)5 (38%)
853 (23%)5 (38%)

Across all 64 studies, recruiting or not: 67% stop at 75 or younger and 66% at 65; 13% take children; 2% are for women only and 88% for men only; 31% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Oligospermia studies take

Of 16 interventional studies with no phase under Oligospermia, half reached primary completion within 26 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase26 mo17–36 · 16 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 64. Browse all 64 → or search them.